Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MUL001
- Development stage
- Preclinical
- Lead developer
- Mulberry Biotherapeutics
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Intratumoral
01
Overview
MUL001 is an investigational live-attenuated bacterial therapy being developed by Mulberry Biotherapeutics for the treatment of neurofibromatosis type 2-related schwannomatosis (NF2-SWN) and other slow-growing tumors. The active ingredient is an attenuated strain of Salmonella Typhimurium, which is administered via image-guided intratumoral injection directly into tumors. The therapy works through immune activation within hypoxic tumor microenvironments, with the bacteria selectively targeting and modulating the tumor microenvironment. MUL001 is based on research from Harvard University and Massachusetts General Hospital and is licensed exclusively from MGH. The company is currently in the IND-enabling phase of development and has received orphan drug designation in both the US and Europe. Beyond NF2-SWN, the platform is being evaluated for additional indications including NF1-associated neurofibromas, non-NF2 schwannomatosis, and meningioma.
Beyond the preview
Go deeper on MUL001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MUL001.